🔗 Share this article

While America proceeds with historic adjustments to its vaccination recommendations, one figure has surfaced unexpectedly: Tracy Beth Høeg, a Danish American sports medicine doctor and public health researcher who rose to prominence by questioning coronavirus vaccinations during the global health crisis and has zeroed in on potential deaths following Covid immunization in her brief tenure at the US Food and Drug Administration (FDA).

Proposed Changes to Pediatric Vaccine Schedule

Health officials were set to reveal sweeping changes to the childhood vaccination calendar in December, bringing the US with the Danish vaccine program, it is understood – a significant shift that would put the US out of alignment with much of the global community with little proof for public health gain. This reveal has been delayed until the next year.

Instead of the top vaccines chief, Tracy Beth Høeg is set to address the audience at the gathering. She was recently named acting director of the FDA’s CDER, the fifth individual to lead the office this year.

A New Direction at the Regulatory Body

This interim role could signify a strengthened alliance between the pharmaceutical and biologics branches as Høeg and Prasad consolidate power at the regulatory agency – and it signals a increased emphasis upon rolling back long-standing vaccines at the FDA.

The new acting director has often pushed for ending certain childhood vaccine recommendations in the US in order to be more in line with the Danish model, a society with comprehensive healthcare and a citizenry approximately the population of the state of Wisconsin.

In her initial comments, she has persisted in emphasizing on vaccination policy – typically the responsibility of Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than medication approval.

Questions Over Qualifications

The appointee has little discernible experience in medication creation, regulation or administrative roles, which has been typical for previous leaders of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a senior adviser to the FDA chief and CBER since spring.

“She appears not to have the requisite experience” for overseeing the drug-regulation department, stated Dr. Jonathan Howard. “She lacks experience running a scientific study. She is not versed in managing a large organization. She has no expertise in pharmaceutical oversight.”

Former directors of the center would “understand legal statutes and the research of medication creation”, said Dr. Janet Woodcock. “Clearly, she lacks the type of experience that prior appointees who led CBER have had.”

CDER has an immense workload at the agency, she emphasized.

“The public just pays attention on the innovative therapies, but the generic program authorizes a multitude of generic drugs. There is also a biologic copycat branch, non-prescription drug unit and more, and all of those need to be managed,” she explained. “The responsibility you don’t keep your eye on, that is the part that I always told people is going to cause problems.”

Furthermore, a substantial administrative element to the position, which oversees over 5,000 staff members. “It is a huge management job, if you execute it properly,” she added.

Official Statement and Controversial Policies

In response to concerns about Høeg’s qualifications and whether this appointment signifies more teamwork among FDA leaders on vaccines, a representative said that the “concerns are based on inaccurate presumptions”.

“Her resume matches the responsibilities of her job,” the spokesperson explained, pointing to the time Høeg spent advising the agency head on “medication safety and approval science, including computational safety modeling and shot safety tracking”.

As the temporary head, Dr. Høeg inherits the agency head's recently launched priority voucher program, a disputed expedited drug-approval program that allegedly worried her predecessors. “By what process are these drugs being chosen for this expedited pathway? Who makes the choices?” Howard said. “There’s a lot of lack of transparency going on at the FDA right now.”

Broadly speaking, he said, “the FDA looks to be trending towards more relaxed rules of all drugs, except for shots.”

Established Past Work on Vaccines

With vaccines, Dr. Høeg has a more documented, if troubling, track record, some experts observe. She published a research paper using non-validated crowd-sourced reports to determine the rate of heart inflammation following COVID-19 immunization. She consulted for the Florida surgeon general Joseph Ladapo, who was said to have altered data to indicate Covid vaccinations are more dangerous than they are.

Part of her “policy goals” for the incoming government included revising rules for new vaccines and discontinuing “non-essential” immunizations, she stated post-election on a online show. At the FDA, Dr. Høeg has allegedly floated the idea of excluding young men from getting Covid vaccines.

“She’s an all-around ideologue who begins with her preconceived notions and tailors the evidence to fit the evidence in a extremely misleading, dishonest way,” Dr. Howard argued.

Consolidating Power and a “Push for Payback”

Dr. Høeg became part of fellow dissenters, {like|